Ad5.F35-hGCC-PADRE vaccine / Thomas Jefferson University, Liminatus - LARVOL DELTA

A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma (clinicaltrials.gov) - P2 | N=48 | Active, not recruiting | Sponsor: Thomas Jefferson University | N=81 ➔ 48

Enrollment change • Colorectal Adenocarcinoma • Colorectal Cancer • Esophageal Adenocarcinoma • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Gastric Adenocarcinoma • Gastric Cancer • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Small Intestinal Carcinoma • Solid Tumor

A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma (clinicaltrials.gov) - P2 | N=81 | Active, not recruiting | Sponsor: Thomas Jefferson University | Suspended ➔ Active, not recruiting | Trial completion date: Dec 2024 ➔ Mar 2027 | Trial primary completion date: Jul 2024 ➔ Mar 2026

Enrollment closed • Trial completion date • Trial primary completion date • Colorectal Adenocarcinoma • Colorectal Cancer • Esophageal Adenocarcinoma • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Gastric Adenocarcinoma • Gastric Cancer • Gastrointestinal Cancer • Gastrointestinal Disorder • Hepatology • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Small Intestinal Carcinoma • Solid Tumor

A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma (clinicaltrials.gov) - P2 | N=81 | Suspended | Sponsor: Thomas Jefferson University | Trial primary completion date: Mar 2024 ➔ Jul 2024

Surgery • Trial primary completion date • Colorectal Adenocarcinoma • Colorectal Cancer • Esophageal Adenocarcinoma • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Gastric Adenocarcinoma • Gastric Cancer • Gastrointestinal Cancer • Gastrointestinal Disorder • Hepatology • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Small Intestinal Carcinoma • Solid Tumor

A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma (clinicaltrials.gov) - P2 | N=81 | Suspended | Sponsor: Thomas Jefferson University | Recruiting ➔ Suspended

Surgery • Trial suspension • Colorectal Adenocarcinoma • Colorectal Cancer • Esophageal Adenocarcinoma • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Gastric Adenocarcinoma • Gastric Cancer • Gastrointestinal Cancer • Gastrointestinal Disorder • Hepatology • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Small Intestinal Carcinoma • Solid Tumor

A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma (clinicaltrials.gov) - P2 | N=81 | Recruiting | Sponsor: Thomas Jefferson University | Phase classification: P2a ➔ P2

Phase classification • Colorectal Adenocarcinoma • Colorectal Cancer • Esophageal Adenocarcinoma • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Gastric Adenocarcinoma • Gastric Cancer • Gastrointestinal Cancer • Gastrointestinal Disorder • Hepatology • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Small Intestinal Carcinoma • Solid Tumor

Liminatus Pharma LLC and Iris Acquisition Corp to combine to incorporate and accelerate much-needed cancer treatments (Businesswire) - "Liminatus Pharma LLC...and Iris Acquisition Corp...announced they have entered into a definitive business combination agreement. Upon closing of the transaction, the combined company will be renamed 'Liminatus Pharma, Inc.'....As part of the agreement the new entity is expected to develop three much-needed cancer treatments which have originated from the Thomas Jefferson University (TJU) in the US and a South Korean biotech firm, Innobation Bio Ltd. ('Innobation')....The immune-modulating cancer treatments being developed by Liminatus are a GCC Vaccine, GCC CAR-T therapy and a CD47 immune checkpoint inhibitor....The transaction is expected to be completed in the first half of 2023."

Commercial • Licensing / partnership • Colorectal Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor

A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma (clinicaltrials.gov) - P2a; N=81; Recruiting; Sponsor: Thomas Jefferson University; Trial primary completion date: Dec 2022 ➔ Mar 2024

Clinical • Trial primary completion date • Colorectal Adenocarcinoma • Colorectal Cancer • Esophageal Adenocarcinoma • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Gastric Adenocarcinoma • Gastric Cancer • Gastrointestinal Cancer • Gastrointestinal Disorder • Hepatology • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor

Phase 2A Study of Ad5.F35-hGCC-PADRE in Gastrointestinal Malignancies (clinicaltrials.gov) - P2a; N=81; Recruiting; Sponsor: Thomas Jefferson University; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Colorectal Adenocarcinoma • Colorectal Cancer • Esophageal Adenocarcinoma • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Gastric Adenocarcinoma • Gastric Cancer • Gastrointestinal Cancer • Gastrointestinal Disorder • Neuroendocrine Tumor • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Sarcoma • Solid Tumor

Phase 2A Study of Ad5.F35-hGCC-PADRE in Gastrointestinal Malignancies (clinicaltrials.gov) - P2a; N=81; Not yet recruiting; Sponsor: Thomas Jefferson University; Initiation date: Apr 2020 ➔ Sep 2020

Clinical • Trial initiation date • Colorectal Adenocarcinoma • Colorectal Cancer • Esophageal Adenocarcinoma • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Gastric Adenocarcinoma • Gastric Cancer • Gastrointestinal Cancer • Neuroendocrine Tumor • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • Thoracic Cancer

Phase 2A Study of Ad5.F35-hGCC-PADRE in Gastrointestinal Malignancies (clinicaltrials.gov) - P2a; N=81; Not yet recruiting; Sponsor: Thomas Jefferson University; Initiation date: Dec 2019 ➔ Apr 2020

Clinical • Trial initiation date